DISEASE OVERVIEW
Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic, progressive, fibrosing interstitial pneumonia [1] . The disease, which occurs primarily in older adults, is limited to the lungs and is associated with the radiological and/or histopathologic pattern of usual interstitial pneumonia (UIP) [2, 3] . Radiological UIP is characterized on high-resolution computed tomography (HRCT) by the presence of reticular opacities, often associated with traction bronchiectasis, typically in a basal, subpleural and patchy distribution [4] . However, a definite diagnosis of UIP on HRCT requires the presence of honeycombing, which manifests as clustered cystic airspaces, usually of comparable diameter on the order of 3-10 mm (Fig. 1 ) [5] . Histopathologic UIP consists of a combination of fibrotic areas with scarring and honeycomb change alternate with areas of less affected or even normal lung parenchyma (Fig. 2) . The fibrotic zones are composed mainly of dense collagen, although scattered subepithelial foci of proliferating fibroblasts and myofibroblasts (so-called fibroblastic foci) are a consistent finding. Notably, a pattern of UIP can be found in a number of conditions including, among others, connective tissue disease (CTD), chronic hypersensitivity pneumonitis (HP) and pneumoconioses (especially asbestosis), which makes it essential a rigorous and multidisciplinary approach to the diagnosis of IPF (e.g., idiopathic UIP) [6] . This point remains unappreciated by many physicians, and, as a Incidence and prevalence of IPF increase dramatically with age. Indeed, the disease is virtually absent in patients younger than 50 years of age, but is present in an estimated 0.2% of those older than 75 years of age [7, 8] .
The underlying causes of the fibrotic response in IPF remain unknown. However, cigarette smoking, exposure to metal and wood dust, microbial agents, chronic microaspiration secondary to gastro-oesophageal reflux and genetic abnormalities have all been associated with an increased risk of developing the disease [9] [10] [11] [12] [13] . Consistent with the progressive nature of the fibrotic process, shortness of breath on exertion is the most common presenting symptom. IPF is almost invariably fatal with a 5-year survival of approximately 20% and a mortality burden higher than that of many cancers [14] . Yet, its clinical course and rate of progression are highly variable and unpredictable. In fact, periods of relative stability may be punctuated by episodes of accelerated deterioration, so-called 'acute exacerbations' often resulting in respiratory failure and death [15, 16] . Moreover, a subgroup of patients, predominantly smoking males, display an accelerated clinical course and have a gene expression pattern that is different from those with slower progression and longer survival [17] .
Our understanding of IPF has undergone dramatic change in the last two decades, and this has affected the approach to treatment. Indeed, older pathogenetic models of chronic active inflammation leading to fibrosis have evolved to current models of repeated alveolar epithelial cell micro-injury and dysregulated repair response in the presence of relatively little inflammation [18] . open-label trial [33] , safety and efficacy of pirfenidone in patients with IPF were initially evaluated in a phase 2 double-blind, placebo-controlled, multicenter study conducted in Japan by Azuma et al. [34] . This trial was stopped prematurely following an interim analysis revealing that episodes of acute exacerbation of IPF (AE-IPF) had occurred exclusively in the placebo arm (n = 5; 14% vs. 0% in the pirfenidone arm; P = 0.0031) during the 9-month study period. The change in the lowest oxygen saturation (SpO2) during a 6-min exercise test (6MET), the primary endpoint, did not reach statistical significance (P = 0.0722). However, in a pre-specified analysis of patients who maintained a SpO2[80% during a 6MET at baseline, the lowest SpO2 during a 6MET improved in the pirfenidone group at 6 and 9 months (P = 0.0069 and P = 0.0305, respectively).
Positive treatment effects were also demonstrated in the change in vital capacity (VC) at 9 months (P = 0.0366). Following these promising data, Taniguchi and colleagues conducted a multicenter, double-blind, placebo-controlled phase three study in which 275 Japanese patients were randomized in a 2:1:2 ratio to high-dose (1800 mg/day) or low-dose (1200 mg/day) pirfenidone, or placebo [35] . The study met its primary endpoint of change in VC from baseline to week 52. In fact, the rate of decline of VC was lower in both the high-dose (-0.09 L) and low-dose pirfenidone arms (-0.08 L) compared to the placebo arm (-0.16 L; P = 0.042 and P = 0.039, respectively). Significant differences were also observed in progression-free survival time (defined as time to death and/or C10% decline in VC from baseline) between the high-dose and the placebo arms (P = 0.028) and in change in total lung capacity (TLC) between the low-dose and the placebo arms (P = 0.040). However, a limitation of this study was that the primary endpoint was changed before unblinding, which possibly hampered the integrity of the study. Overall, pirfenidone was well tolerated. The most common drug-related adverse event was photosensitivity (observed in 51% of patients in the high-dose group and 53% in the low-dose group), which was mild in severity in most cases and not a major reason for discontinuation of the study. FVC decline of at least 10% (P = 0.001). By contrast, in study 006, the between-group difference in FVC change at week 72 was not significant (P = 0.501), although, a consistent pirfenidone effect was apparent until week 48 (P = 0.005) and in an analysis of all study time points (P = 0.007). Mean change in percentage predicted FVC was -9.0% in the pirfenidone arm and -9.6% in the placebo arm. Most common pirfenidone-related adverse events included nausea (36% vs. 17% in placebo), dyspepsia (19% vs. 7%), vomiting (14% vs. 4%), anorexia (11% vs. 4%), photosensitivity (12% vs. 2%), skin rash (32% vs. 12%), and dizziness (18% vs. 10%). However, they were generally mild to moderate in severity, reversible, and without clinically significant sequelae.
These trials had sufficient methodological quality to be included in a Cochrane meta-analysis that showed that pirfenidone significantly reduces the rate of functional decline and risk of disease progression compared with placebo [37] .
In 2011, pirfenidone has been approved for the treatment of IPF in Europe, but not by the US Food and Drug Administration (FDA), which requested an additional phase 3 study to confirm efficacy. In the ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF; ClinicalTrials.gov identifier, NCT01366209) study, 555 patients with IPF were randomly assigned to receive either pirfenidone 2403 mg/day (n = 278) or placebo (n = 277) for 52 weeks [23] . Of note, to enroll patients at higher risk for disease progression, certain aspects of the CAPACITY study design were modified such as exclusion of patients with major airflow limitation (ratio of the forced expiratory volume in one second (FEV1) to P\0.001] was seen in the pirfenidone compared to the placebo arm. A series of sensitivity analyses confirmed the robustness of these findings and the estimated magnitude of pirfenidone effect (e.g., an approximate 50% reduction in FVC decline) in patients with IPF [38] . Pirfenidone treatment reduced also the decline in the 6MWD (P = 0.04) and improved progression-free survival (e.g., time to the first occurrence of any one of the following: a confirmed decrease of C10% in the percentage of the predicted FVC, a confirmed decrease of 50 m or more in the 6MWD, or death; P\0.001). No significant differences between pirfenidone and placebo were found in dyspnea scores (P = 0.16) or in all-cause (4.0% vs. 7.2%; P = 0.10) or IPF-related mortality (1.1% vs.
2.5%; P = 0.23). However, a pre-specified pooled analysis from the ASCEND and CAPACITY trials showed that pirfenidone significantly reduced both death from any cause [3.5% vs. 6.7 %; hazard ratio (HR) 052; P = 0.01] and from IPF (1.1% vs. 3.5 %; HR 0.32; P = 0.006) compared with placebo at week 52.
Similar to the CAPACITY trials, gastrointestinal and skin-related events were more common in the pirfenidone group than in the placebo group, although they were generally mild to moderate in severity, reversible, and without clinically significant sequelae. Moreover, the proportion of adverse events leading to discontinuation of study treatment did not differ between the pirfenidone (40 patients; 14.4%) and the placebo groups (30 patients;
10.8%).
Recommendations on optimal management of pirfenidone-related adverse events based on existing guidelines, research evidence, and expert opinion have recently been published [39] . In
October 2014 the FDA granted pirfenidone fast track, priority review, orphan product, and breakthrough designation. Several reports have confirmed long-term favorable safety and efficacy profiles of pirfenidone [40] [41] [42] . In particular, an interim analysis of RECAP, an ongoing open-label, long-term, follow-up extension study that included patients who completed the CAPACITY or ASCEND trials, showed that almost 50% of the patients initially randomized to pirfenidone were still receiving therapy after 5-year follow-up [41] . Nintedanib showed a trend towards a reduction in the annual rate of decline in FVC, the primary endpoint. Specifically, the adjusted annual rate of decline in FVC was 0. 
ANTIACID THERAPY
Gastroesophageal reflux (GER), including clinically silent GER, is highly prevalent in patients with IPF [50, 51] , and markers of aspiration (e.g., bile acids and pepsin) are significantly elevated in bronchoalveolar lavage fluid (BALF) from patients with IPF compared to patients with interstitial lung disease other than IPF and healthy controls [52] . In addition, levels of inflammatory biomarkers such as lactate dehydrogenase, alkaline phosphatase, C-reactive protein, and TNF-a are higher in BALF of patients with newly diagnosed IPF compared to patients with newly diagnosed GER disease [53] . Chronic microaspiration secondary to GER is considered a risk factor for the development or worsening of the disease, suggesting that prevention of microaspiration could have an important role in the management of IPF.
In an uncontrolled retrospective study of 204 patients with IPF, antiacid treatment (AAT) was associated with reduced radiological fibrosis and was an independent predictor of longer survival time [54] . In addition, a post hoc analysis of data from patients assigned to placebo arms in three IPFnet-sponsored randomized-controlled trials (RCTs) revealed that patients taking AAT at baseline [either proton-pump inhibitors or H 2 blockers; n = 124/242 (51%)] had a smaller decrease in FVC at 30 weeks compared with those not taking AAT (P = 0.05) after adjusting for sex, baseline percentage predicted FVC, and baseline percentage predicted DL CO [55] ).
However, a more recent post hoc analysis of patients in the placebo arms of three large RCTs
[n = 624, 291 of whom (47%) were taking AAT at baseline] showed that AAT did not improve progression-free survival (defined as FVC decrease C10%, 6MWD decrease C50 m, or death), FVC decline, hospitalization and all-cause and IPF-related mortality, but was associated with a significantly higher rate of all-cause hospitalization (HR 1.4, P = 0.042) [56] . Despite the lack of evidence from prospective RCTs, the 2015 guidelines recommend AAT for most patients with IPF based on the potential benefit and the favorable side effect profile of antiacid medications [25] . However, further research focusing on efficacy and long-term safety of AAT in patients with IPF is clearly needed.
MOST DEVELOPED COMPOUNDS FOR IPF
Historically, the pharmaceutical industry has been reluctant to invest in research and development of drugs for rare diseases like IPF [57] . The last decade has witnessed a growing interest in IPF and a willingness among 
IW001
Ongoing adaptive immune response against autoantigens is thought to play an important role in disease progression in some IPF patients [59] . Type V collagen (col(V)) is a minor collagen normally sequestered within the lung interstitium and, therefore, hidden from the immune system. Lung injury may lead to col(V) exposure, making it available for activation of an autoimmune response [60] . A sustained autoimmune response against col(V), which is present in approximately 50% of patients, may result in abnormal lung remodeling and fibrotic changes [61, 62] . In a recently published phase 1 study (ClinicalTrials.gov identifier, NCT01199887), an orally available compound that induces immune tolerance to col(V) (IW001;
ImmuneWorks, Inc, Indianapolis, IN, USA), was safe and well tolerated, and showed a trend towards stabilization of FVC and metalloproteinase 7 levels in anti-col(V) Ab ? patients with IPF [63] . Further study with col(V) oral immunotherapy is warranted to confirm the therapeutic effect of IW001 in patients with IPF.
TD139
Galectin-3, a member of the galectin family of galactoside binding lectins, has been shown to play a central role in fibrosis development and progression through the activation of macrophages and recruitment and activation of myofibroblasts [64] . TD139 (Galecto Biotech AB, Copenhagen, Denmark) is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3 formulated for inhalation.
Safety and tolerability of TD139 in patients with IPF are currently being evaluated in a phase 1b/ 2a trial (ClinicalTrials.gov identifier, NCT02257177).
BMS-986020
Lysophosphatidic acid (LPA) is a well-recognized mediator of wound healing and tissue fibrosis [65] , and LPA receptor 1 (LPA1) appears to contribute to the development of IPF by inducing epithelial cell apoptosis, fibroblast recruitment and vascular leak [66] . The safety and efficacy of BMS-986020 (Bristol-Myers Squibb, New York, NY, USA), a high-affinity, selective, small-molecule antagonist of LPA1 in patients with IPF is currently being assessed in a phase 2 trial (ClinicalTrials.gov identifier, NCT01766817).
FG-301
It is a humanized monoclonal antibody directed against connective tissue growth factor (CTGF), a key mediator of tissue remodeling and fibrosis. 
STX-100
STX-100 (Biogen, Weston, MA, USA) is a humanized monoclonal antibody against the integrin avb6, which functions as a key mediator of TGF-b activation and plays an important functional role in promoting and maintaining fibrogenesis and epithelial injury [76] . In murine bleomycin-induced pulmonary fibrosis, partial inhibition of avb6 effectively inhibits TGF-b activation, epithelial injury, and tissue fibrosis [77] . The safety and tolerability of subcutaneously administered multiple, escalating doses of STX-100 in patients with IPF are being evaluated in a phase 2 study, which is currently recruiting participants (ClinicalTrials.gov identifier, NCT01371305).
CONCLUSIONS
IPF is a progressive and almost invariably fatal disease. Over the last decade, our knowledge of the mechanisms involved in disease pathobiology has substantially improved and this had allowed a number of clinical trials of pharmacological interventions to be undertaken and completed. This massive effort of the medical and industry community has produced the approval of two drugs of comparable safety and efficacy profile, pirfenidone and nintedanib, which will soon become standard of care worldwide (Table 2 ).
Yet, this is only the beginning as neither pirfenidone nor nintedanib is a cure for IPF, neither drug improves lung function and most patients continue to progress while on treatment. These limitations notwithstanding, the concerted effort by the scientific, professional and patient community as well as the pharmaceutical industry has the potential to finally develop a real cure for patients suffering from this devastating disease. 
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